The report “Protein Binding Assays Market by Technology (Equillibrium Dialysis, Ultrafiltration, Ultracentrifugation, Gel Filtration Chromatography), End User (Pharmaceutical & Biotechnology Companies, Contract Research Organization) - Global Forecast to 2023", The global protein binding assays market is projected to reach USD 425.7 million in 2023 from USD 256.1 million in 2018, at CAGR of 10.7%.
The increasing use of protein binding assays in pre-clinical research for studying the distribution properties of the drug, and the growing number of drug discovery activities, the minimizing drug discovery and development costs, and the increase in pharmaceutical R&D expenditure is driving the growth of this market.
Based on technology, equilibrium dialysis segment is expected to grow at the highest CAGR in the market during the forecast period
On the basis of technology, the global protein binding assays market is divided into equilibrium dialysis, ultrafiltration, ultracentrifugation, and other technologies. In 2018, the equilibrium dialysis segment is expected to grow at the highest CAGR in the protein binding assays market. The growth can be attributed to the technique’s physical simplicity, low cost, and high accuracy. It is also considered as a gold standard technique for protein binding studies.
Download PDF Brochure@
Based on end user, Contract Research Organizations (CROs) segment is expected to grow at the highest CAGR in the market during the forecast period
On the basis of end user, the global protein binding assays market is divided into pharmaceutical and biotechnology companies, CROs, and other end users. In 2018, the CROs segment is expected to grow at the highest CAGR in the global protein binding assays market. This high growth can be attributed to the increase increased protein binding studies for drug discovery & development by pharmaceuticals and the growing focus of biotechnology companies on developing biologics.
Target Audience:
# Government and academic institutes
# Protein binding assay providers
# R&D departments
# Contract research organizations
# Pharmaceutical & biotechnology companies
# Consulting firms
# Government associations
Asia Pacific is expected to grow at the highest CAGR during the forecast period
The APAC market is projected to register the highest growth rate during the forecast period primarily due to factors such as, growth of clinical trial activities in several APAC countries. As a result of this, the pharmaceutical and biopharmaceutical companies are outsourcing their drug discovery and development activities to APAC-based CROs. This is one of the major factors driving the growth of the protein binding assay market in the Asia Pacific.
Objectives of the Study:
# To define, describe, and forecast the protein binding assay market on the basis of technology, end user, and regions.
# To provide detailed information about factors influencing market growth (drivers, restraints, opportunities, and industry-specific challenges).
# To strategically analyze the micromarkets with respect to individual growth trends, prospects, and contributions to the overall market.
# To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players.
# To forecast the size of the market segments with respect to four major regional segments, namely, North America, Europe, Asia Pacific, and the Rest of the World (RoW).
# To profile the key players in the market and comprehensively analyze their market positions and core competencies.
# To track and analyze competitive developments such as partnerships, agreements, and joint ventures; mergers and acquisitions; product development; and research and development activities in the protein binding assay market.
Request Sample Pages@
Market Players
The key players in the global protein binding assays market are HTDialysis (US), Thermo Fisher Scientific (US), Merck (Germany), and Sovicell (Germany).
Most companies focus on agreements, collaborations, and partnerships to compete in the market. The players also focus on increasing their presence in high-growth markets through acquisitions and product launches. Thermo Fisher (US), Sovicell (Germany) and 3B Pharmaceutical focus on partnerships, collaboration and license agreements to strengthen their position in the market.
